Assessing the impact of haemodynamic monitoring with CardioMEMS on heart failure patients: a cost–benefit analysis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Codina, Pau
- dc.contributor.author Vicente Gómez, José Ángel
- dc.contributor.author Hernández Guillamet, Guillem
- dc.contributor.author Ricou Ríos, Laura
- dc.contributor.author Carrete, Andrea
- dc.contributor.author Vilalta, Victoria
- dc.contributor.author Estrada Cuxart, Oriol
- dc.contributor.author Ara del Rey, Jordi
- dc.contributor.author Lupón, Josep
- dc.contributor.author Bayés-Genís, Antoni
- dc.contributor.author López Seguí, Francesc, 1991-
- dc.date.accessioned 2024-10-14T09:47:35Z
- dc.date.available 2024-10-14T09:47:35Z
- dc.date.issued 2024
- dc.description.abstract Aims: The objective of this study was to perform a cost–benefit analysis of the CardioMEMS HF System (Abbott Laboratories, Abbott Park, IL, USA) in a heart failure (HF) clinic in Spain by evaluating the real-time remote monitoring of pulmonary artery pressures, which has been shown to reduce HF-related hospitalizations and improve the quality of life for selected HF patients. Particularly, the study aimed to determine the value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower and its effectiveness remains uncertain. Methods and results: This single-centre study enrolled all consecutive HF patients (N = 43) who had been implanted with a pulmonary artery pressure sensor (CardioMEMS HF System); 48.8% were females, aged 75.5 ± 7.0 years, with both reduced and preserved left ventricular ejection fraction; 67.4% of them were in New York Heart Association Class III. The number of HF hospitalizations in the year before and the year after the sensor implantation was compared. Quality-adjusted life years gained based on a literature review of previous studies were calculated. The rate of HF hospitalizations was significantly lower at 1 year compared with the year before CardioMEMS implantation (0.25 vs. 1.10 events/patient-year, hazard ratio 0.22, P = 0.001). At the end of the first year, the usual management outperformed the CardioMEMS HF System. By the end of the second year, the CardioMEMS system is estimated to reduce costs compared with usual management (net benefits of €346). Conclusions: Based on the results, we suggest that remote monitoring of pulmonary artery pressure with the CardioMEMS HF System represents a midterm and long-term efficient strategy in a healthcare setting in Southern Europe.
- dc.format.mimetype application/pdf
- dc.identifier.citation Codina P, Vicente JÁ, Hernández G, Ricou L, Carrete A, Vilalta V, et al. Assessing the impact of haemodynamic monitoring with CardioMEMS on heart failure patients: a cost–benefit analysis. ESC Heart Failure. 2024 Aug;11(4):1955-62. DOI: 10.1002/ehf2.14698
- dc.identifier.doi http://dx.doi.org/10.1002/ehf2.14698
- dc.identifier.issn 2055-5822
- dc.identifier.uri http://hdl.handle.net/10230/61386
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof ESC Heart Failure. 2024 Aug;11(4):1955-62
- dc.rights © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword Cost–benefit
- dc.subject.keyword Pulmonary pressure sensor
- dc.subject.keyword Monitoring
- dc.subject.keyword Hospitalizations
- dc.subject.keyword Heart failure
- dc.title Assessing the impact of haemodynamic monitoring with CardioMEMS on heart failure patients: a cost–benefit analysis
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion